TAS Minutes 26th May 2026(334 KB) - TAS
Date added: 24th Jun 2026
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| TIRZEPATIDE (Mounjaro®) (UPDATED) | Green | Management of overweight and obesity |
For managing overweight and obesity in adults in line with NICE TA1026. March 2026: Green for eligible cohort only as per LLR weight management guide |
| BECLOMETASONE DIPROPIONATE Extra fine / FORMOTEROL (Fostair NEXThaler®) | Green |
Asthma COPD |
2nd Choice Dry Powder LLR Adult Asthma Guideline (≥18 years) AIR and MART FAQ The LLR COPD guidelines have been updated (June 2026) and ICS/LABA combinations are no longer routinely recommended as a treatment option. No NEW initiations. For patients established on this therapy, treatment should be reviewed on a case-by-case basis, taking into account clinical stability and patient preference. Ongoing prescribing should be in line with the updated COPD guidelines. |
| CICLOSPORIN EYE DROPS (Verkazia®) | Yellow | Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents | |
| CIPROFLOXACIN LIQUID | Green |
As per recommendations in LLR antimicrobial guidelines. Particular formulation listed stocked in Omcare service in primary care for when prescribed by PTCDA and virtual ward teams. |
|
| Dexcom ONE+® (UPDATED) | Yellow | Diabetes Continuous glucose monitoring (CGM) |
Dexcom ONE+ ® is approved for use in Leicester, Leicestershire and Rutland for diabetes glucose monitoring where a patient meets the criteria detailed in the LLR APC position statement.
|
| FEZOLINETANT (Veoza®) (NEW) | Yellow | for treating moderate to severe vasomotor symptoms associated with menopause |
Usually recommended and initiated by secondary care specialists. However, primary care clinicians with a specialist interest, appropriate experience, and competency in menopause management may initiate treatment. In line with NICE TA1143 Funding from: 29th June 2026.
|
| GOSERELIN | Yellow | Endometriosis, uterine fibroids | |
| GOSERELIN 3.6mg (Zoladex®) (UPDATED) | Yellow | Breast cancer |
Zoladex 3.6mg implant is the only licensed product for breast cancer
|
| INFLIXIMAB | Red | All indications |
As indicated on the LLR Medicines Formulary |
| LEUPRORELIN | Yellow | Endometriosis, uterine fibroids | |
| LEUPRORELIN (PROSTAP 3 DCS ®) | Yellow | Breast cancer |
3 monthly preparation |
| LEVOFLOXACIN TABLETS (NEW) | Green |
As per recommendations in LLR antimicrobial guidelines. Particular formulation listed stocked in Omcare service in primary care for when prescribed by PTCDA and virtual ward teams. |
|
| MAINTELYTE SOLUTION (NEW) | Red | Maintenance of Fluid |
For use in adult ICU only |
| TRIPTORELIN | Yellow | Endometriosis, uterine fibroids |
Other Updates on this Website
Recent documents from LLR APC and TAS
LLRAPC Newsletter – June 2026(529 KB) - LMSG/LLR APC newsletters
Date added: 19th Jun 2026
ADHD Paediatric SCA Request form(56 KB)
Date added: 11th Jun 2026
Adult ADHD Shared Care Request Form National Format(407 KB) - Shared care agreement
Date added: 29th Dec 2022
RMOC Style Generic Shared Care Request Form(68 KB) - Shared care agreement
Date added: 14th Nov 2022
Agomelatine Shared Care Agreement(328 KB) - Shared care agreement
Date added: 13th Jan 2021
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more